STAT

Opinion: Expanding drug courts won’t help ease the opioid crisis

The White House's opioid commission recommends a major expansion of drug courts nationwide, but that won't ease the epidemic of opioid use and overdoses.

Wednesday’s report from the White House’s opioid commission recommends a major expansion of drug courts nationwide.

Drug courts — courts that impose mandated, abstinence-based treatment on people arrested for drug possession, with close judicial oversight — arose in the 1980s and ’90s as a laudable attempt to ease the devastating effects of the war on drugs. Today, there are more than 3,100 drug courts in the U.S., up from just one in 1989 and 665 in 2000. Half of all U.S. counties now have at least one operating drug court.

Yet available evidence does not support their continued expansion.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks